19 September 2018
("ImmuPharma" or the "Company")
Appointment of Joint Brokers
ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company's NOMAD and broker.
Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma said:
"As per our recently announced corporate update, we are looking forward with confidence to the future progress of ImmuPharma. As part of our continued proactive investor relations strategy, we also look forward to working with Stanford Capital and SI Capital as part of our corporate advisory team."
For further information please contact:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.